Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women.

Danik JS, Buring JE, Chasman DI, Zee RY, Ridker PM, Glynn RJ.

J Thromb Haemost. 2013 Jan;11(1):205-8. doi: 10.1111/jth.12056. No abstract available.

2.

Non-O blood group: an important genetic risk factor for venous thromboembolism.

Franchini M, Makris M.

Blood Transfus. 2013 Apr;11(2):164-5. doi: 10.2450/2012.0087-12. Epub 2012 Oct 11. No abstract available.

3.

beta2-adrenergic receptor polymorphism and venous thromboembolism.

Folsom AR, Peacock JM, Boerwinkle E, Cushman M.

Thromb Haemost. 2008 Jan;99(1):240. doi: 10.1160/TH07-08-0520. No abstract available.

4.

Role of soluble P-selectin and methylenetetrahydrofolate reductase gene polymorphisms (677C>T) in Egyptian patients with venous thromboembolism.

Tawfik NM, Deeb ME, Nasr AS.

Blood Coagul Fibrinolysis. 2012 Sep;23(6):537-42. doi: 10.1097/MBC.0b013e32835523ba.

PMID:
22688557
5.

The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis.

Tiedje V, Dunkler D, Ay C, Horvath B, Quehenberger P, Pabinger M, Zielinski C, Pabinger I, Mannhalter C.

Thromb Haemost. 2011 Nov;106(5):908-13. doi: 10.1160/TH11-04-0278. Epub 2011 Sep 8.

PMID:
21901234
6.

Lack of association of non-synonymous FUT2 and ALPL polymorphisms with venous thrombosis.

Tregouet DA, Sabater-Lleal M, Bruzelius M, Emmerich J, Amouyel P, Dartigues JF, Kieler H, Morange PE.

J Thromb Haemost. 2012 Aug;10(8):1693-5. doi: 10.1111/j.1538-7836.2012.04807.x. No abstract available.

PMID:
22672431
7.

Interaction between blood type, smoking and factor V Leiden mutation and risk of venous thromboembolism: a Danish case-cohort study.

El-Galaly TC, Kristensen SR, Overvad K, Steffensen R, Tjønneland A, Severinsen MT.

J Thromb Haemost. 2012 Oct;10(10):2191-3. doi: 10.1111/j.1538-7836.2012.04772.x. No abstract available.

PMID:
22577971
8.

Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type.

Sode BF, Allin KH, Dahl M, Gyntelberg F, Nordestgaard BG.

CMAJ. 2013 Mar 19;185(5):E229-37. doi: 10.1503/cmaj.121636. Epub 2013 Feb 4.

9.

Association of ADAMDEC1 haplotype with high factor VIII levels in venous thromboembolism.

Berger M, Moscatelli H, Kulle B, Luxembourg B, Blouin K, Spannagl M, Lindhoff-Last E, Schambeck CM.

Thromb Haemost. 2008 May;99(5):905-8. doi: 10.1160/TH08-01-0059.

PMID:
18449420
10.

Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism.

Ray JG.

Curr Opin Pulm Med. 2008 Sep;14(5):369-73. doi: 10.1097/MCP.0b013e328307ee38. Review.

PMID:
18664964
11.

25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants.

Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard BG.

J Thromb Haemost. 2013 Mar;11(3):423-31. doi: 10.1111/jth.12118.

PMID:
23279309
12.

Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study.

Kristinsson SY, Goldin L, Turesson I, Hultcrantz M, Björkholm M, Landgren O.

J Thromb Haemost. 2012 May;10(5):962-4. doi: 10.1111/j.1538-7836.2012.04676.x. No abstract available.

PMID:
22372994
13.

P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism.

Ay C, Jungbauer LV, Kaider A, Koder S, Panzer S, Pabinger I, Mannhalter C.

Thromb Haemost. 2008 May;99(5):899-904. doi: 10.1160/TH07-11-0672.

PMID:
18449419
14.

Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy.

Ritch JM, Kim JH, Lewin SN, Burke WM, Sun X, Herzog TJ, Wright JD.

Obstet Gynecol. 2011 Jun;117(6):1367-74. doi: 10.1097/AOG.0b013e31821bdd16.

PMID:
21606747
15.

Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients.

Gauthier K, Kovacs MJ, Wells PS, Le Gal G, Rodger M; REVERSE investigators.

J Thromb Haemost. 2013 Jan;11(1):200-3. doi: 10.1111/jth.12048. No abstract available.

PMID:
23114022
16.

Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of venous thromboembolism in Chinese population.

Li YY, Zhai ZG, Yang YH, Pang BS, Wang HY, Zhang W, Zhao L, Wang J, Wang C.

Thromb Res. 2011 Apr;127(4):324-7. doi: 10.1016/j.thromres.2010.11.034. Epub 2011 Feb 12.

PMID:
21320716
17.

Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations.

Lippi G, Franchini M, Targher G.

Clin Chim Acta. 2011 May 12;412(11-12):797-801. doi: 10.1016/j.cca.2011.01.018. Epub 2011 Jan 21. Review.

PMID:
21256836
18.

Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis.

Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, Kyrle P, Poli D, Tait RC, Iorio A.

BMJ. 2011 Feb 24;342:d813. doi: 10.1136/bmj.d813. Review.

19.

Thrombin generation as an intermediate phenotype for venous thrombosis.

Segers O, van Oerle Rv, ten Cate Ht, Rosing J, Castoldi E.

Thromb Haemost. 2010 Jan;103(1):114-22. doi: 10.1160/TH09-06-0356. Epub 2009 Nov 13.

PMID:
20062924
20.

Lp(a) lipoprotein redux--from curious molecule to causal risk factor.

Kathiresan S.

N Engl J Med. 2009 Dec 24;361(26):2573-4. doi: 10.1056/NEJMe0910792. No abstract available.

PMID:
20032327
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk